Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 12HER2-positive Breast Cancer 6Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Rare Tumor 1Lung Neoplasms 1Locally Advanced Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-positive Advanced Breast Cancer 1HER2-expressing Advanced Solid Tumors 1HER2 Positive Breast Cancer 1HER2 Insertion Mutation Positive Advanced NSCLC 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasm Female 1Breast Cancer Metastatic 1Breast Cancer Invasive 1Breast Cancer Female 1Advanced Breast Cancer 1

Interventions

dalpiciclib 2trastuzumab deruxtecan 1sacituzumab govitecan 1pyrotinib 1pegfilgrastim 1patritumab deruxtecan 1olaparib 1fluzoparib 1apatinib 1Ga(III)-DOTATOC 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Breast Cancer Metastatic × pyrotinib × Clear all
NCT06718933 2025-02-06

Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis

Fudan University

Phase 1/2 Recruiting
74 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡